DNA vaccine and methods for its use
AssigneeJohn Wayne Cancer Institute
InventorsDave S. B. Hoon, Yasufumi Kaneda
Life of this patent
Estimating the term…
Abstract
DNA cancer vaccines and methods for their use are described. The vaccines are comprised of viral liposomes comprising nucleic acid, preferably DNA, encoding a tumor-associated antigen. The viral liposomes may be formed by the fusion of HVJ reagents with nonviral reagents. The vaccine may be administered subcutaneously, intradermally, intramuscularly or into an organ. The vaccine may be administered to induce a host normal cell to express the tumor associated antigen.
Claims33
A vaccine comprising, in an amount effective to suppress or attenuate melanoma growth upon administration to a human, viral liposomes comprising a fusigenic HVJ polypeptide and DNA encoding a melanoma-associated antigen, wherein said viral liposomes do not include live viral particles.
A composition comprising viral liposomes prepared from HVJ reagents, wherein:
- said liposomes comprise DNA encoding one or more melanoma-associated antigens;
- and
- wherein said liposomes fiurher comprise HMG-1 protein and do not include live viral paticles;
- and
- wherein intramuscular administration of said composition induces an immune response against at least one of said melanoma-associated antigens;
- and
- wherein said immune response is sufficient to suppress or attenuate melanoma growth.
A composition comprising viral liposomes prepared from HVJ reagents, wherein:
- said liposomes comprise DNA encoding a plurality of melanoma-associated antigens;
- and
- wherein said liposomes further comprise HMG-1 protein and do not include live viral particles;
- and
- wherein intramuscular administration of said composition induces an immune response against at least one of said melanoma-associated antigens.
Dependencies are inferred from the claim text.